Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Aug 1;10:2389–2400. doi: 10.2147/CMAR.S162887

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Xiao et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Suppression of LRH-1 in HepG2 attenuates its growth in vivo.

Notes: (A and B) Growth curve shows the growth patterns of tumors formed by HepG2^LRH-1/− cell clones and parental HepG2 cells, HepG2 cells formed xenograft tumors with larger sizes and at faster rates as compared to HepG2^LRH-1/− #1 cells, while HepG2^LRH-1/− #2 lost the in vivo tumorigenic capacity in all nude mice (NT, no tumor). (C) Ki67 immunohistochemistry. Our results suggested that significantly lower and less Ki67 immunoreactivity was seen in xenograft tumors formed from HepG2^LRH-1/− than parental HepG2 cells. Scale bar =100 μm.** P<0.01 vs parental HepG2 cells.